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In Japan, neuroblastoma (NB) occupies 8 % of pediatric malignancies and 150 -200 
patients were diagnosed each year. Many patients come in advanced stage of disease. In NB, the 
stages of disease and tumor biology affect the outcome. About 20-30% of NB patients have MYCN 
amplification, which was detected from surgical biopsy of tumor tissues. The MYCN amplification 
is already known to correlate with poor outcome, and advanced stage of disease. The recent 
advances in cancer diagnosis is inclination toward liquid biopsy method. With its relatively less 
invasive properties, liquid biopsy is a promising diagnosis method of cancer. One method of liquid 
biopsy is by analyzing the level of exosomal miRNA in peripheral blood samples of NB patients. 
Our study aimed to find differentially expressed miRNAs between plasma and tissue which may 
have potential to be used as biomarkers, particularly for unfavorable NB patients, using Next 
Generation Sequencing (NGS) platform.  
 
Materials and Methods 
 We extracted exosomal miRNAs from 31 plasma and 37 tissue samples of untreated NB 
patients diagnosed in Hiroshima University Hospital and its affiliated hospitals. We made NGS 
libraries from those samples, and sequenced them using MiSeq, a NGS machine. Raw counts of 
miRNA, obtained after sequencing, were normalized using 6 miRNAs (miR-24, miR-484, miR-93-
5p, miR-191-5p, miR-126-3p and miR-16-5p) which has been reported to have consistent expression. 
We then analyzed the correlation between plasma or tissue expression levels of miRNAs and the 
clinical factors including staging by International Neuroblastoma Risk Group Staging System 
(INRGSS), outcome, and MYCN status. In INRGSS staging, we divided into M stage (n = 11 
(plasma), 15 (tissue)) and non M stage cases (n = 20 (plasma), 22 (tissue)). In outcome analysis 
group, we divided into deceased cases (n = 10 (plasma), 16 (tissue)) and alive with disease-free 
cases (n = 21 (plasma), 21 (tissue)). In MYCN analysis group, we divided into non-amplified cases 
(n = 25 (plasma), 26 (tissue)) and amplified cases (n = 6 (plasma), 11 (tissue)). We chose statistically 
significant miRNAs with similar expression pattern in both plasma and tissue samples in each of 
the 3 analyses groups above. We combined those miRNAs and obtained the most significant 
combination of miRNAs that might be useful as biomarkers.  
 
Results 
In the correlation to outcomes, miRNA-92a-3p was upregulated significantly in deceased 
cases both in plasma (p = 0.017) and tissue samples. Average expression levels in plasma of miRNA-
92a-3p were 1069.1 & 594.3 in deceased and alive cases, respectively. Focusing more on significance 
of miR-92a-3p to outcome, we classified its expression levels into two category based on the average 
level (732.15) of miRNA-92a-3p expressions in all cases of outcome analyses group. Those cases 
whose miRNA-92a-3p expression levels were less than 732.15, showed favorable outcome, with 5-
years overall survival rate was 89%. On the other hand, the overall survival rate of cases whose 
expression levels were more than 732.15, was only 45 %. In correlation to INRGGS staging, 
miRNA-375 was upregulated significantly in M stage cases both in plasma (p = 0.002) and tissue 
samples (p =0.008). Average expression levels in plasma of miRNA-375 were 509 and 16.3 in M and 
non M stage cases, respectively. In correlation to MYCN status, miRNA 92a-3p and miR-99a-5p 
were upregulated significantly in MYCN amplified cases both in plasma (p = 0.007 & 0.006) and 
tissue samples (p =0.001 & 0.001). Average expression levels in plasma samples for miR-92a-3p 
were 1296.7 and 596.6 in amplified and non-amplified cases, respectively. While average miR-99a-
5p expression levels in plasma were 5.6 and 0.7 in amplified and non-amplified cases, respectively. 
We found that combination of miR-92a-3p, miR-375 & miR-99a-5p has higher stratifying indicator 
than any other combination of significant miRNAs found in our study (AUC = 0.726, p = 0.001, 
95 % CI = 0.612-0.841, sensitivity = 77 %, specificity = 56.7 %).  
 
Discussion 
Micro RNA 92a-3p was reported as an oncomir which targets cadherin 1 (CDH1) genes in 
negative relationship, subsequently affected β-catenin signaling pathway in glioma. Expression of 
miRNA-375 might be linked to tumorigenic neuroblastic cell phenotype. The N-Myc protein 
(product of MYCN gene) may possibly upregulate miR-375 and suppress expression of HuD, a 
neuronal-specific RNA-binding protein which affects neuronal differentiation. This will result in 
inhibition of neuronal differentiation of neuroblastic cells. Finally miR-99a-5p was reported as a 
tumor-suppressor miRNA in other cancer such as breast cancer and small cell lung cancer. 
Limitation of our study is the quality of the original sample. Hemolysis and blood coagulation were 
known to affect exosome yield because blood cells contains a lot of exosome and miRNAs. There 
might be a possibility that this was also happened in our study even though we used hemolysis-
free samples. Therefore, careful attention should be paid to serum or plasma samples preparation 
for subsequent exosomal miRNA sequencing studies. 
 
Conclusion 
We found that combination of miR-92a3p, miR-375 & miR-99a-5p may be used as 
biomarker particularly for diagnosis of unfavorable NB. We realized that further validation step 
needs to be done on larger number of NB patients. 
 
 
